Alzinova AB

78D

Company Profile

  • Business description

    Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is engaged in the development of a specific oligomer-directed vaccine (ALZ-101), and ALZ-201 which is a monoclonal antibody that is specific for the toxic AB oligomers. The products of the company are in the clinical and preclinical stages of development as a therapeutic vaccine for the treatment of Alzheimer’s.

  • Contact

    Entreprenorsstraket 10
    Molndal431 53
    SWE

    https://www.alzinova.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    5

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,841.908.300.09%
CAC 407,696.2758.28-0.75%
DAX 4023,787.45146.68-0.61%
Dow JONES (US)44,828.53344.110.77%
FTSE 1008,822.910.29-0.00%
HKSE23,916.06153.88-0.64%
NASDAQ20,601.10207.971.02%
Nikkei 22539,810.8824.980.06%
NZX 50 Index12,766.6062.120.49%
S&P 5006,279.3551.930.83%
S&P/ASX 2008,603.007.200.08%
SSE Composite Index3,472.3211.170.32%

Market Movers